Detailed Notes on M3541
The first stop place was the safety and tolerability of sifalimumab. Treatment method-emergent adverse events (AEs) and critical AEs (SAEs) and their severity, final result, and any relationship on the research medication ended up recorded by the investigator through the entire review. AEs had been considered more likely to be related to analyze me